11252 Federal Register / Vol. 76, No. 40 / Tuesday, March 1, 2011 / Notices 

who did not participate in the IFPS II. 

All IFPS II participants who completed 

at least two surveys after their infants 

were born and for whom current contact 

information can be found will be sent 

the mailed questionnaire. This is 

expected to be about 2,562 participants. 

We estimate that 1,538 respondents will 

return it and that it will take a 

respondent 20 minutes (0.33 hours) to 

complete the questionnaire, for a total of 

513 hours. An additional 522 mothers 

are expected to complete the telephone 

interview of 20 minutes (0.33 hours) for 

a total of 174 hours. An estimated 1,380 

participants will return the 

demographic questionnaire, which will 

require 5 minutes (0.08 hours) to 

complete for a total of 110 hours. Thus, 

the total estimated burden is 839 hours. 

FDA’s burden estimate is based on prior 

experience with consumer surveys that 

are similar to this proposed data 

collection. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

Portion of study No. of 

respondents 

Annual 

frequency 

per response 

Total annual 

responses 

Hours per 

response Total hours 

Pretest mailed questionnaire ............................................... 91 1 91 0.42 38 

Pretest telephone interview ................................................. 9 1 9 0.42 4 

Main study mailed questionnaire ......................................... 1,538 1 1,538 0.33 513 

Main study telephone interview ........................................... 522 1 522 0.33 174 

Demographic questionnaire ................................................. 1,380 1 1,380 0.08 110 

Total .............................................................................. ........................ ........................ ........................ ........................ 839 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

II. References 

The following reference has been 

placed on display in the Division of 

Dockets Management (see ADDRESSES) 

and may be seen by interested persons 

between 9 a.m. and 4 p.m., Monday 

through Friday. 

1. Fein, Sara B., Judith Labiner-Wolfe, 

Katherine Shealy, et al., ‘‘Infant Feeding 

Practices Study II: Study Methods,’’ 

Pediatrics 2008; 122(suppl 2): S28–S35. 

Dated: February 22, 2011. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2011–4459 Filed 2–28–11; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 USC, 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group; Training 

and Career Development Subcommittee. 

Date: March 9–10, 2011. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Eliane Lazar-Wesley, 

Ph.D., Health Scientist Administrator, Office 

of Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 4245, MSC 

9550, 6001 Executive Blvd., Bethesda, MD 

20892–9550, 301–451–4530, el6r@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA– 

K Conflicts. 

Date: March 9, 2011. 

Time: 5 p.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 4238, MSC 

9550, 6001 Executive Blvd., Bethesda, MD 

20892–9550, 301–402–6626, 

gml45a@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Pharmacological Development of Treatment 

Agents and Formulations or Tobacco 

Dependence. 

Date: March 18, 2011. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Jose F. Ruiz, Ph.D., 

Scientific Review Officer, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, Room 4228, MSC 9550, 

6001 Executive Blvd., Bethesda, MD 20892– 

9550, (301) 451–3086, ruizjf@nida.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; High 

Throughput Screening for Nicotinic Receptor 

Subunits. 

Date: March 24, 2011. 

Time: 2:30 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 4238, MSC 

9550, 6001 Executive Blvd., Bethesda, MD 

20892–9550, 301–402–6626, 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Training in Computational Neuroscience 

(T90/R90). 

Date: March 30, 2011. 

Time: 12 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Minna Liang, Ph.D., 

Scientific Review Officer, Grants Review 

Branch, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, Room 

4226, MSC 9550, 6001 Executive Blvd., 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 76, No. 40 / Tuesday, March 1, 2011 / Notices 11253 

Bethesda, MD 20892–9550, 301–435–1432, 

liangm@nida.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Training in Neuroimaging (T90) (RFA DA11– 

006). 

Date: March 31, 2011. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Scott A Chen, PhD, 

Scientific Review Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 4234, MSC 

9550, 6001 Executive Blvd., Bethesda, MD 

20892–9550, 301–443–9511, 

chensc@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos.: 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: February 23, 2011. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–4544 Filed 2–28–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

MAPGen and MAPGenKB studies. 

Date: March 16, 2011. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: YingYing Li-Smerin, MD, 

PhD, Scientific Review Officer, Office of 

Scientific Review/DERA, National Heart, 

Lung, and Blood Institute, 6701 Rockledge 

Drive, Room 7184, Bethesda, MD 20892– 

7924, 301–435–0277, lismerin@nhlbi.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Cardiovascular Integrity and Remodeling. 

Date: March 17, 2011. 

Time: 9 a.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Giuseppe Pintucci, PhD, 

Scientific Review Officer, Review Branch/ 

DERA, National Heart, Lung, and Blood 

Institute, 6701 Rockledge Drive, Room 7192, 

Bethesda, MD 20892, 301–435–0287, 

Pintuccig@nhlbi.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Informatics Tools and Services to Support 

Data Sharing and Distribution for 

Cardiovascular, Lung, and Blood 

Researchers. 

Date: March 18, 2011. 

Time: 2 p.m. to 4:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Youngsuk Oh, PhD, 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7182, Bethesda, MD 20892–7924, 301–435– 

0277, yoh@mail.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Strategy for Finding Cases of Moderate-toSevere COPD. 

Date: March 22, 2011. 

Time: 2 p.m. to 3 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Youngsuk Oh, PhD, 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7182, Bethesda, MD 20892–7924, 301–435– 

0277, yoh@mail.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Phenotype finder in data resources review 

meeting. 

Date: March 23, 2011. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Renaissance, Washington, DC Hotel, 

999 Ninth Street, NW., Washington, DC 

20001–4427. 

Contact Person: Keith A. Mintzer, PhD, 

Scientific Review Officer, Review Branch/ 

DERA, National Heart, Lung, and Blood 

Institute, 6701 Rockledge Drive, Room 7186, 

Bethesda, MD 20892–7924, 301–435–0280, 

mintzerk@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: February 23, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–4548 Filed 2–28–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Diabetes Biomarkers 

Ancillary Studies. 

Date: March 28, 2011. 

Time: 10 a.m. to 11 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892. (Telephone 

Conference Call). 

Contact Person: Paul A. Rushing, PhD, 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes Of Health, 

Room 747, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8895, 

rushingp@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK Ancillary 

Studies. 

Date: March 30, 2011. 

Time: 12 p.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892. (Telephone 

Conference Call). 

Contact Person: Barbara A Woynarowska, 

PhD, Scientific Review Officer, Review 

Branch, DEA, NIDDK, National Institutes Of 

Health, Room 754, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 

402–7172, woynarowskab@niddk.nih.gov. 


jlentini on DSKJ8SOYB1PROD with NOTICES